Join to View Full Profile
18433 Roscoe Blvd#208Northridge, CA 91325
Phone+1 818-341-4401
Fax+1 818-341-4402
Dr. Chow is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Christopher Chow, MD, is an internal medicine specialist based in Northridge, CA. Dr. Chow completed a residency in internal medicine at Cedars-Sinai Medical Center from 1999 to 2002 after graduating from New York Medical College in 1999. Involvement in clinical trials includes studies on the efficacy and safety of Orforglipron for peripheral artery disease, the Proact study on REACT for Type 2 diabetes mellitus with chronic kidney disease, and research on Tirzepatide in Type 2 diabetes mellitus patients. Dr. Chow has received multiple CMS Meaningful Use Stage 1 and Stage 2 Certifications from athenahealth, Inc. from 2011 to 2017.
Education & Training
Los Angeles County-Harbor-UCLA Medical CenterResidency, Pulmonary Disease and Critical Care Medicine, 2019 - 2025
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1999 - 2002
New York Medical CollegeClass of 1999
Certifications & Licensure
CA State Medical License 2000 - 2026
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification athenaClinicals, athenahealth, Inc., 2011, 2013-2017
- CMS Meaningful Use Stage 1 Certification athenaClinicals, athenahealth, Inc., 2011, 2013-2017
- CMS Meaningful Use Stage 1 Certification athenaClinicals EHR, athenahealth, Inc, 2012-2013
Clinical Trials
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2017 May 24
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease Start of enrollment: 2025 Oct 31
- Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease Start of enrollment: 2022 Jan 05
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
